Agenus | AGEN - Current Liabilities


Agenus reported $323.49M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Agenus USD 323.49M 36.36M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Celldex Therapeutics USD 50.99M 4.53M Dec/2025
CSL USD 4.61B 207M Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Glaxosmithkline GBP 28.82B 144.79M Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
Intrexon USD 23.02M 38K Jun/2024
J&J USD 54.13B 3.26B Dec/2025
Jiangsu Hengrui CNY 6.37B 1.48B Dec/2025
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
MacroGenics USD 43.11M 1.36M Dec/2025
Merck EUR 9.04B 405M Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Northwest Biotherapeutics USD 87.9M 3.98M Sep/2025
Novartis USD 27.28B 4.72B Dec/2025
Novavax USD 459.95M 30.08M Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Veracyte USD 59.94M 12.22M Dec/2025